Get the Stockscreener App
3.40
4.76%
-0.17
After Hours:
3.40
Kodiak Sciences Inc stock is traded at $3.40, with a volume of 590.29K.
It is down -4.76% in the last 24 hours and down -18.27% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$3.57
Open:
$3.55
24h Volume:
590.29K
Relative Volume:
1.44
Market Cap:
$179.38M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-0.9043
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-1.16%
1M Performance:
-18.27%
6M Performance:
-49.03%
1Y Performance:
+12.58%
1-Day Range:
$3.35
$3.65
1-Week Range:
$3.35
$3.8069
52-Week Range:
$1.92
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
3.40 | 181.51M | 0 | -197.68M | -158.88M | -3.76 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference | KOD Stock News - GuruFocus
Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize
Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus
Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus
Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan
Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World
MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter
MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
JPMorgan Chase & Co. Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
Stealth biotech bags rights to VelaVigo bispecific in $440M deal - Fierce Biotech
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Advances Retinal Therapies with Promising Pipeline - TipRanks
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):